These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 24908142)

  • 21. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.
    Lugli A; Tzankov A; Zlobec I; Terracciano LM
    Mod Pathol; 2008 Nov; 21(11):1403-12. PubMed ID: 18587323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.
    Yamagishi H; Imai Y; Okamura T; Fukuda K; Ono Y; Ban S; Inoue T; Ueda Y
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1815-22. PubMed ID: 23808938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.
    Lubomierski N; Plotz G; Wormek M; Engels K; Kriener S; Trojan J; Jungling B; Zeuzem S; Raedle J
    Cancer; 2005 Sep; 104(5):952-61. PubMed ID: 16015629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
    García-Solano J; Conesa-Zamora P; Carbonell P; Trujillo-Santos J; Torres-Moreno D D; Pagán-Gómez I; Rodríguez-Braun E; Pérez-Guillermo M
    Int J Cancer; 2012 Oct; 131(8):1790-9. PubMed ID: 22287190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
    Groisman GM; Meir A; Sabo E
    Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
    Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
    Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between genetic alterations and prognosis in sporadic colorectal cancer.
    Chang SC; Lin JK; Yang SH; Wang HS; Li AF; Chi CW
    Int J Cancer; 2006 Apr; 118(7):1721-7. PubMed ID: 16231316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF; Navina S; Cressman KL; Pai RK
    Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CK7 and consensus molecular subtypes as major prognosticators in
    Loupakis F; Biason P; Prete AA; Cremolini C; Pietrantonio F; Pella N; Dell'Aquila E; Sperti E; Zichi C; Intini R; Dadduzio V; Schirripa M; Bergamo F; Antoniotti C; Morano F; Cortiula F; De Maglio G; Rimassa L; Smiroldo V; Calvetti L; Aprile G; Salvatore L; Santini D; Munari G; Salmaso R; Guzzardo V; Mescoli C; Lonardi S; Rugge M; Zagonel V; Di Maio M; Fassan M
    Br J Cancer; 2019 Oct; 121(7):593-599. PubMed ID: 31474758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
    Ricciardiello L; Ceccarelli C; Angiolini G; Pariali M; Chieco P; Paterini P; Biasco G; Martinelli GN; Roda E; Bazzoli F
    Clin Cancer Res; 2005 Jun; 11(11):4234-40. PubMed ID: 15930362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
    Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
    Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
    Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
    Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
    Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.
    Bayrak R; Yenidünya S; Haltas H
    Pathol Res Pract; 2011 Mar; 207(3):156-60. PubMed ID: 21282015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.
    Kim JH; Kang GH
    World J Gastroenterol; 2014 Apr; 20(15):4230-43. PubMed ID: 24764661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
    Kermanshahi TR; Jayachandran P; Chang DT; Pai R
    Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDX-2 expression is reduced in colorectal carcinomas with solid growth pattern and proximal location, but is largely independent of MSI status.
    Okoń K; Zazula M; Rudzki Z; Papla B; Osuch C; Stachura J
    Pol J Pathol; 2004; 55(3):9-14. PubMed ID: 15619975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma.
    Saad RS; Cho P; Silverman JF; Liu Y
    Am J Clin Pathol; 2004 Sep; 122(3):421-7. PubMed ID: 15362373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
    Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
    J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.